The cure rate for nonmetastatic rectal cancer has been improving for decades but often includes unpleasant treatments, wrote Hanna K. Sanoff, M.D., M.P.H. in an Editorial published by The New England Journal of Medicine (NEJM) on June 5, 2022.
Recent phase 3 trial findings have increased treatment intensity to include multiagent chemotherapy in addition to radiation therapy before proctectomy is performed.
Such treatment has resulted in a 3-year disease-free survival rate of up to 77%.
Rectal Cancer Study Produced Very Promising Treatment Results
Millions of COVID-19 Shots Ready for Children Under 5: White House
Children under 5 are the only age group in the United States not yet eligible for COVID-19 shots
Screening Mammography Levels Not Fully Restored After Pandemic Drop
While mammography, biopsies, and cancer diagnoses are up from 2020 lows, none have reached pre-COVID-19 volumes
In Utero SARS-CoV-2 Exposure Tied to Neurodevelopmental Sequelae
Maternal SARS-CoV-2 positivity during pregnancy linked to greater rate of neurodevelopmental diagnoses in offspring within first year of life
One in Nine May Get Delayed Large Local Reaction After Moderna Vaccine
Higher risk seen among women and among individuals aged 30 to 69 years
COVID-19 Testing Requirement Lifted for Travelers Flying to the U.S.
CDC has determined the regulation is no longer necessary, but will reevaluate the need every 90 days